<DOC>
	<DOCNO>NCT00023673</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Combining one drug give specialize radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study effectiveness radiation therapy combine paclitaxel carboplatin treat patient stage III non-small cell lung cancer .</brief_summary>
	<brief_title>Radiation Therapy Combined With Paclitaxel Carboplatin Treating Patients With Stage III Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose 3-dimensional conformal radiotherapy administer concurrently paclitaxel carboplatin patient inoperable stage IIIA IIIB non-small cell lung cancer . ( Phase I ) ( Closed accrual 01/13/04 . ) - Determine 12-month survival rate patient treat regimen . ( Phase II ) ( Closed accrual 11/27/07 . ) - Determine toxicity regimen patient . - Determine partial organ tolerance dos lung esophagus patient treat regimen . - Determine complete response rate patient treat regimen . OUTLINE : This multicenter , dose-escalation study 3-dimensional conformal radiotherapy . - Phase I ( close accrual 01/13/04 ) : Patients undergo 3-dimensional conformal radiotherapy daily five day week 7-8 week . Patients also receive concurrent chemotherapy comprise paclitaxel IV 1 hour follow carboplatin IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 , 43 . Cohorts 7-9 patient receive de-escalating dos 3-dimensional conformal radiotherapy maximum tolerate dose ( MTD ) determine give combination chemotherapy . The MTD define high dose 1 patient experience dose-limiting toxicity . - Phase II : Additional patient accrue treated MTD . At least 3 week complete radiotherapy , patient may receive additional chemotherapy comprise paclitaxel IV 3 hour carboplatin IV 30 minute . Treatment paclitaxel carboplatin may repeat every 3 week 2 course . Patients follow every 3 month 1 year , every 4 month 1 year , every 6 month 3-5 year , annually thereafter . PROJECTED ACCRUAL : A maximum 73 patient ( 27 phase I [ close accrual 10/28/04 ] 46 phase II ) accrue study within 1-1.5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm unresectable stage IIIB nonsmall cell lung cancer Squamous cell carcinoma Adenocarcinoma Large cell carcinoma Nonsmall cell carcinoma otherwise specify All detectable primary tumor involve regional lymph node must encompass radiotherapy field Measurable disease 3dimensional planning CT scan No undifferentiated small cell ( oat cell highgrade neuroendocrine ) carcinoma No stage IV recurrent disease No distant metastases supraclavicular lymph node involvement No significant atelectasis ( i.e. , atelectasis entire lung ) No pleural effusion , pericardial effusion , superior vena cava syndrome No lung cancer within past 2 year Ineligible currently open Radiation Therapy Oncology Group ( RTOG ) phase III lung protocol PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin le 1.5 mg/dL Aspartate aminotransferase ( AST ) less 2 time upper limit normal Renal : Creatinine great 2.0 mg/dL Pulmonary : Forced expiratory volume ( FEV ) _1 least 1.0 L Other : Not pregnant nursing Fertile patient must use effective contraception No weight loss great 5 % past 6 month No malignancy within past year except nonmelanoma skin cancer Completed 3D plan total lung V20 &lt; /= 30 % mean esophageal dose &lt; /= 34 Gy esophageal V55 &lt; /= 30 % PRIOR CONCURRENT THERAPY : Biologic therapy : No prior biologic response modifier current lung cancer At least 5 year since prior biologic response modifier Chemotherapy : No prior chemotherapy current lung cancer At least 5 year since prior chemotherapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics No prior radiotherapy thorax Surgery : No prior complete tumor resection</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>adenosquamous cell lung cancer</keyword>
</DOC>